Centrient Pharmaceuticals India Pvt Ltd
Next 500 2018
+ 2 More
+ 2 More
Share
Share
OVERVIEW
FINANCIALS
Featured In Fortune India Ranking
Next 500 India
#191(2018)#197(2017)#113(2015)
#191(2018)#197(2017)#113(2015)
Financial Data 2023
Revenue
1,911
(INR Cr)
Net Operating Income
1,851
(INR Cr)
Assets
741
(INR Cr)
Profit
53
(INR Cr)
Net Worth
658
(INR Cr)
Financial Data
RevenueNet Operating IncomeProfitAssetsNet Worth
| PARAMETERS | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 1911 16.6% | 1638 2.4% | 1600 8.2% | 1478 -1.0% | 1493 6.6% | 1400 15.0% | 1218 2.8% | 1185 -15.0% | 1394 2.5% | 1360 23.0% | 1106 33.6% | 828 -5.2% | 873 - |
| Net Operating Income (INR Cr) | 1851 13.90% | 1625 3.54% | 1570 5.35% | 1490 2.62% | 1452 2.64% | 1415 14.51% | 1236 8.95% | 1134 -16.40% | 1356 0.07% | 1355 22.80% | 1104 33.93% | 824 -5.46% | 872 0.00% |
| Profit (INR Cr) | 53 -31.4% | 78 -22.5% | 100 102.2% | 50 33.2% | 37 -54.0% | 81 - | 0 -98.7% | 8 -88.6% | 73 109.5% | 35 -37.3% | 55 - | -10 - | -26 - |
| Assets (INR Cr) | 741 -1.5% | 752 7.2% | 701 14.3% | 614 18.4% | 519 -9.4% | 572 11.9% | 512 -0.4% | 514 -8.4% | 561 33.5% | 420 24.8% | 336 29.6% | 260 3.7% | 250 - |
| Net Worth (INR Cr) | 658 8.8% | 605 14.9% | 527 23.5% | 426 12.9% | 378 11.8% | 338 30.6% | 259 -11.7% | 293 2.9% | 284 34.4% | 212 19.7% | 177 46.4% | 121 -7.1% | 130 0.0% |
| Employee Cost (INR Cr) | 99 12.7% | 87 3.9% | 84 11.1% | 76 23.4% | 61 -13.8% | 71 26.3% | 56 -0.3% | 57 8.3% | 52 - | 0 - | 0 - | 0 - | 0 - |
| Interest Cost (INR Cr) | 16 | 17 | 13 | 25 | 22 | 25 | 29 | 27 | 19 | 4 | 9 | 9 | 10 |
| Cash & Bank Balance (INR Cr) | 42 | 42 | 68 | 53 | 39 | 60 | 0 | 39 | 24 | 42 | 22 | 16 | 34 |
| Total Debt (INR Cr) | 0 | 74 | 86 | 104 | 104 | 192 | 214 | 214 | 268 | 162 | 160 | 139 | 120 |
Key Financial Ratios
Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
| PARAMETERS | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 2.8% | 4.7% | 6.3% | 3.4% | 2.5% | 5.8% | 0.0% | 0.7% | 5.2% | 2.6% | 5.0% | - | - |
| Profit As % Of Assets | 7.2% | 10.3% | 14.3% | 8.1% | 7.2% | 14.1% | 0.0% | 1.6% | 13.0% | 8.3% | 16.5% | - | - |
| Profit As % Of Networth | 8.1% | 12.8% | 19.0% | 11.6% | 9.9% | 23.9% | 0.0% | 2.8% | 25.6% | 16.4% | 31.4% | - | - |
| Interest Cost to EBITDA % | 12.1% | 11.1% | 8.1% | 19.8% | 35.7% | 15.7% | 67.0% | 51.5% | 23.9% | 6.6% | 11.9% | 104.7% | - |
| Debt to Equity Ratio | - | 0.12 | 0.16 | 0.24 | 0.28 | 0.57 | 0.83 | 0.73 | 0.94 | 0.77 | 0.90 | 1.15 | 0.93 |
| RONW | 8.4% | 13.7% | 21.0% | 12.3% | 10.4% | 27.1% | 0.0% | 2.9% | 29.4% | 17.2% | 35.5% | - | - |
| ROCE | 11.9% | 16.7% | 22.6% | 18.5% | 13.9% | 27.8% | 5.6% | 8.6% | 21.1% | 13.4% | 21.4% | 0.0% | 0.0% |